Nutcracker Syndrome

MagDI is an emerging, largely investigational procedure. The first human cases were performed in late 2021, and current evidence comes from small prospective and multicenter studies with mostly one-year follow-up. Unlike the SADI-S and duodenal switch, it does not yet have established society endorsement or long-term durability data, so availability is limited and often study-based. Discuss current status directly with a bariatric program (Gagner et al., Surgery for Obesity and Related Diseases, 2024).

Yes, in the right patient. LINX is one of the few good surgical options for reflux after a sleeve. In carefully selected patients it can control symptoms and end daily acid-reducing medication without a larger conversion operation (Grover and Khaitan, Diseases of the Esophagus, 2023; Patel et al., Surgical Endoscopy, 2022). The key word is "selected," and the most important selection criterion is a proven, normally functioning esophagus.

Reflux is common after sleeve gastrectomy, affecting roughly 20–30% of patients over the long term (Vosburg et al., American Society for Metabolic and Bariatric Surgery, 2026). A standard fundoplication such as a Nissen usually is not possible after a sleeve, because the fundus used to build the wrap was removed (Patel et al., Surgical Endoscopy, 2022). LINX avoids that problem. It is a ring of magnetic titanium beads placed laparoscopically around the lower esophageal sphincter to keep a weak valve closed while still allowing swallowing (Khaitan et al., Obesity Surgery, 2023).

Why esophageal function must be proven normal first:

• The esophagus has to open the device. A fundoplication still relaxes naturally when you swallow. The LINX magnets stay closed until food is pushed through them, so all the work falls on the contraction strength of the esophagus (Eriksson et al., Diseases of the Esophagus, 2023).
• Weak or absent peristalsis means trouble swallowing. An esophagus without enough pushing power may not be able to open the magnets, which can cause persistent difficulty swallowing. The FDA instructions for use list these as precautions:
  • Distal esophageal contractions weaker than 35 mmHg.
  • Fewer than 70% effective (propulsive) swallows.
  • Known motility disorders such as achalasia, distal esophageal spasm, nutcracker esophagus, or a hypertensive lower esophageal sphincter (Telem et al., Surgical Endoscopy, 2017).

An esophagus with no peristalsis at all (aperistalsis) rules out LINX (Bell, The Esophagus, 2021).

• Reflux can be mimicked. Achalasia can cause heartburn and regurgitation that look like GERD. Performing an antireflux procedure on a misdiagnosed patient can cause severe swallowing problems. For that reason, the American College of Gastroenterology recommends high-resolution manometry before any antireflux procedure and specifically before LINX (Katz et al., American College of Gastroenterology, 2022).
• Contractile reserve matters. In the prospective post-sleeve LINX study, patients qualified only if they had one of two findings (Novia et al., Surgical Endoscopy, 2025):
  • Normal esophageal motility.
  • Mildly ineffective motility that still showed adequate strength ("reserve") when tested with multiple rapid swallows.

Patients with achalasia, outflow obstruction at the esophagogastric junction (EGJOO), or aperistalsis were excluded.

When patients are chosen this way, results after a sleeve are encouraging:

• Systematic review: 14 studies and 109 patients. Reflux quality-of-life scores improved markedly (GERD-HRQL 38 → 10), and daily PPI use fell from 97.4% to 25.3% at a median of about 19 months (Cammarata et al., Obesity Surgery, 2024).

• Prospective trial: 30 patients, with a significant reduction in daily PPI use in about 96% at 12 months (Khaitan et al., Obesity Surgery, 2023).

• Other series: One series reported that 82% of patients stopped acid medication (Patel et al., Surgical Endoscopy, 2022). A prospective study showed objective normalization of acid exposure in about 64% (Novia et al., Surgical Endoscopy, 2025).

Other requirements for success:

• Hiatal repair: Repairing the hiatus at the same operation is considered essential (Grover and Khaitan, Diseases of the Esophagus, 2023).
• Relative contraindications: Conversion to gastric bypass is usually the better answer in patients with any of the following (Novia et al., Surgical Endoscopy, 2025):
  • BMI of 35 or higher.
  • Hiatal hernia larger than about 3 cm.
  • Severe (grade C–D) esophagitis.
  • Barrett's esophagus.
  • A twisted or narrowed sleeve.

• Side effects: Device-related side effects, mostly temporary swallowing difficulty, occur in about a third of patients. Removal for esophageal erosion is rare, at about 0.9% (Cammarata et al., Obesity Surgery, 2024).

Where LINX sits among the options: conversion to Roux-en-Y gastric bypass remains the most effective and most evidence-supported treatment for refractory reflux after a sleeve. It resolves symptoms in 60–100% of patients and is preferred when BMI is above 35, the sleeve anatomy is abnormal, or esophageal function is impaired (Vosburg et al., American Society for Metabolic and Bariatric Surgery, 2026). LINX is best reserved for patients who meet all of these criteria:

• A normal sleeve.

• A BMI under 35.

• Esophageal motility confirmed to be normal on manometry.

• Reflux that persists despite medication.

The decision should follow a complete workup: endoscopy, barium study, pH testing, and high-resolution manometry (Hawasli et al., American Journal of Surgery, 2019; Cammarata et al., Obesity Surgery, 2024).

‍